Media Summary: In the first part of this roundtable series, Dr. Michael Atkins, of Georgetown Lombardi Comprehensive Cancer Center, and an ... Michael Harrison, MD, Duke University School of Medicine, Durham, NC, discusses real-world quality of life (QOL) outcomes in ... Tian Zhang, MD, MHS, UT Southwestern Medical Center, Dallas, TX, discusses ongoing clinical trials investigating how to ...

Uromigoslive24 Rcc Io Rechallenge Panel - Detailed Analysis & Overview

In the first part of this roundtable series, Dr. Michael Atkins, of Georgetown Lombardi Comprehensive Cancer Center, and an ... Michael Harrison, MD, Duke University School of Medicine, Durham, NC, discusses real-world quality of life (QOL) outcomes in ... Tian Zhang, MD, MHS, UT Southwestern Medical Center, Dallas, TX, discusses ongoing clinical trials investigating how to ... Robert A. Figlin, MD director, division of hematology/oncology, professor of biomedical sciences and medicine, Cedars-Sinai ... A roundtable discussion, moderated by Brian Rini, MD, discussed the latest data from the American Society of Clinical Oncology ... During the second-annual Uromigos Live & Unplugged event, Thomas Powles, MBBS, MRCP, MD; Brian Rini, MD, FASCO; Toni ...

Disclaimer The use of communication, recording and transmission devices on Federal Court premises and during Federal Court ...

Photo Gallery

#UromigosLive24 RCC IO Rechallenge Panel Part 1: CONTACT-03, TiNivo-2 Study Results and Implications
#UromigosLive24 RCC IO Rechallenge Panel Pt 3: IO Therapy After Adjuvant Pembro?
#UromigosLive24 RCC IO Rechallenge Panel Part 4: What About CTLA-4-Based Salvage After IO in RCC?
#UromigosLive24 RCC IO Rechallenge Panel Pt 2: Do We Need a Post-Adjuvant Pembrolizumab Study?
#UromigosLive24 Front-Line Therapy in RCC Panel Part 3: What Data is Forthcoming in Papillary RCC?
Balancing Risks and Rewards in RCC: IO Combinations for Different Patient Profiles
ODYSSEY: real-world QOL outcomes on IO regimens in metastatic RCC
Clinical trials investigating overcoming resistance to ICIs for RCC
IO Rechallenge: Uromigos Live 2024
Selecting I-O Agents and Combinations for Patients With RCC
The Latest Data on IO/TKI Versus IO/IO in Frontline RCC
Uromigos Live 2023: Management of IO-Refractory RCC
Sponsored
Sponsored
View Detailed Profile
#UromigosLive24 RCC IO Rechallenge Panel Part 1: CONTACT-03, TiNivo-2 Study Results and Implications

#UromigosLive24 RCC IO Rechallenge Panel Part 1: CONTACT-03, TiNivo-2 Study Results and Implications

At Uromigos Live 2024, a

#UromigosLive24 RCC IO Rechallenge Panel Pt 3: IO Therapy After Adjuvant Pembro?

#UromigosLive24 RCC IO Rechallenge Panel Pt 3: IO Therapy After Adjuvant Pembro?

In part three of this session, the

Sponsored
#UromigosLive24 RCC IO Rechallenge Panel Part 4: What About CTLA-4-Based Salvage After IO in RCC?

#UromigosLive24 RCC IO Rechallenge Panel Part 4: What About CTLA-4-Based Salvage After IO in RCC?

In the final part of this session, the

#UromigosLive24 RCC IO Rechallenge Panel Pt 2: Do We Need a Post-Adjuvant Pembrolizumab Study?

#UromigosLive24 RCC IO Rechallenge Panel Pt 2: Do We Need a Post-Adjuvant Pembrolizumab Study?

Part two of the

#UromigosLive24 Front-Line Therapy in RCC Panel Part 3: What Data is Forthcoming in Papillary RCC?

#UromigosLive24 Front-Line Therapy in RCC Panel Part 3: What Data is Forthcoming in Papillary RCC?

In part 3 of the session, the

Sponsored
Balancing Risks and Rewards in RCC: IO Combinations for Different Patient Profiles

Balancing Risks and Rewards in RCC: IO Combinations for Different Patient Profiles

In the first part of this roundtable series, Dr. Michael Atkins, of Georgetown Lombardi Comprehensive Cancer Center, and an ...

ODYSSEY: real-world QOL outcomes on IO regimens in metastatic RCC

ODYSSEY: real-world QOL outcomes on IO regimens in metastatic RCC

Michael Harrison, MD, Duke University School of Medicine, Durham, NC, discusses real-world quality of life (QOL) outcomes in ...

Clinical trials investigating overcoming resistance to ICIs for RCC

Clinical trials investigating overcoming resistance to ICIs for RCC

Tian Zhang, MD, MHS, UT Southwestern Medical Center, Dallas, TX, discusses ongoing clinical trials investigating how to ...

IO Rechallenge: Uromigos Live 2024

IO Rechallenge: Uromigos Live 2024

The

Selecting I-O Agents and Combinations for Patients With RCC

Selecting I-O Agents and Combinations for Patients With RCC

Robert A. Figlin, MD director, division of hematology/oncology, professor of biomedical sciences and medicine, Cedars-Sinai ...

The Latest Data on IO/TKI Versus IO/IO in Frontline RCC

The Latest Data on IO/TKI Versus IO/IO in Frontline RCC

A roundtable discussion, moderated by Brian Rini, MD, discussed the latest data from the American Society of Clinical Oncology ...

Uromigos Live 2023: Management of IO-Refractory RCC

Uromigos Live 2023: Management of IO-Refractory RCC

During the second-annual Uromigos Live & Unplugged event, Thomas Powles, MBBS, MRCP, MD; Brian Rini, MD, FASCO; Toni ...

NSD1082/2022 ASIC v Bekier & Ors

NSD1082/2022 ASIC v Bekier & Ors

Disclaimer The use of communication, recording and transmission devices on Federal Court premises and during Federal Court ...